Markets:

Overview

News

Currencies

International

Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

370.44 -7.19 (-1.90%)

Delayed Quote Updated: 3:18 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 Next >

BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

BRUKINSA revenue surged 31% while management raised full-year guidance by $300 million.

Via The Motley Fool

Topics Earnings

BeOne Medicines Q2 Earnings Call Highlights ↗

August 05, 2026

BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued...

Via MarketBeat

Topics Earnings

A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position ↗

July 22, 2026

Executed under pre-established trading plan, this sale reduces the chief executive's direct holdings by just 2%.

Via The Motley Fool

Topics Regulatory Compliance

BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum ↗

February 26, 2026

Via Chartmill

BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan ↗

January 21, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Where BeOne Medicines Stands With Analysts ↗

October 08, 2025

Via Benzinga

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 ↗

June 02, 2026

BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company...

Via MarketBeat

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.

Via The Motley Fool

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.

Via The Motley Fool

Topics Regulatory Compliance

Analyst Expectations For BeOne Medicines's Future ↗

September 18, 2025

Via Benzinga

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗

May 14, 2026

Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.

Via The Motley Fool

Topics Initial Public Offering

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗

May 14, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.

Via The Motley Fool

Topics Regulatory Compliance

This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half ↗

March 19, 2026

Futu Holdings delivers digital brokerage and wealth management solutions to retail and institutional clients across Asia and global markets.

Via The Motley Fool

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

Via The Motley Fool

Topics Regulatory Compliance

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗

February 21, 2026

Don't just buy these stocks. Hold onto them.

Via The Motley Fool

Topics Artificial Intelligence Earnings

HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model ↗

February 20, 2026

Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will...

Via The Motley Fool

Topics Artificial Intelligence Economy

Prediction: These 3 Stocks Will Crush the Market in 2026 ↗

February 16, 2026

These stocks all have catalysts on the way that could provide great news for investors.

Via The Motley Fool

Topics Artificial Intelligence

3 Stocks to Buy in February ↗

February 02, 2026

These three stocks appear to be poised for strong performances in 2026.

Via The Motley Fool

Topics Artificial Intelligence

BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features ↗

December 07, 2025

BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating...

Via Benzinga

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Via Investor's Business Daily

Topics Economy Government

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗

November 17, 2025

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.

Via Benzinga

Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally ↗

October 27, 2025

Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally

Via The Motley Fool

Topics Regulatory Compliance

What's Going On With Summit Therapeutics Stock On Monday? ↗

October 20, 2025

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

Via Benzinga

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 10, 2025

Via Benzinga

Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗

September 07, 2025

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗

September 02, 2025

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.